Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 1997

View Archived Issues

First report of kappa-opioid agonist efficacy in humans

Spotlight on new drugs for cancer

Selective RAR-gamma ligands described by Roche

SmithKline Beecham discloses selective, nonpeptide NK3 antagonists

NK3/NK2 receptor antagonists from SmithKline Beecham

ICN describes antisense oligonucleotides for IL-8 and/or IL-8R

Biota reports new agents for influenza

Novel inhibitors of geranylgeranylation from Baldacci

DuPont Merck prepares anticoagulant aminoboronic acids

GeneMedicine receives quarterly payment from Corange in anticancer gene medicine collaboration

New treatment in development for Pompe's disease

Low-dose diuretic prevents heart failure in the elderly

Medeva acquires license to anthracycline derivative for the treatment of bladder cancer

AmBisome recommended for approval by FDA advisory committee

ProLease drug formulation for the treatment of hormone-mediated disorders enters clinical trials

Lung cancer survival improved with new radiotherapy technique

Helicon Therapeutics: new company focuses on memory disorders and other CNS diseases

GHRH antagonist active in vivo against human renal adenoarcinoma

Genzyme Molecular Oncology and NCI enter drug discovery collaboration

SRI licenses drug formulation technology to Dura

Meridian launches TruJect autoinjector

VA-045 ameliorates head injury-induced neurological dysfunction

Rogaine Extra Strength for Men recommended for approval as OTC

Antiallergic and bronchodilating effects of KF-19514 in guinea pigs

CoCensys to copromote Zarontin for pediatric epilepsy

Syncor to distribute two radiopharmaceuticals from DuPont Merck

TAP receives FDA approval to market new formulation of Lupron Depot

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...